A recent review on stable angina treatments has notably omitted the coronary sinus reducer (CSR), a therapy deemed safe and effective for patients with no other treatment options. Despite evidence from randomized trials and real-life registries supporting its efficacy, CSR was not included in the review, sparking discussions among cardiologists about the importance of considering all available therapies for refractory angina.